Senolytic drugs prevent radiation-induced atrial fibrillation in preclinical study

Publishing in International Immunopharmacology, researchers have identified a potentially preventable cause of atrial fibrillation (AFib)—irregular heart rhythm affecting millions—in patients receiving radiation therapy. The study found that radiation induces cellular senescence in heart tissue through activation of the GATA4-NF-κB pathway, leading to inflammation and electrical remodeling that triggers AFib. Critically, treatment with the senolytic drug combination dasatinib and quercetin (D+Q) successfully prevented this progression in mice. This is significant for multiple reasons: First, it demonstrates that senescent cells directly cause a common, serious cardiac condition, not just contribute to general aging. Second, AFib affects over 30 million people worldwide and dramatically increases stroke risk—any preventive strategy matters. Third, D+Q is already in human clinical trials for other age-related conditions, making translation faster if results hold. While this remains animal research and radiation-induced AFib is a specific subset of cases, it provides proof-of-concept that senolytics can prevent organ-specific functional decline. For cancer survivors receiving chest radiation who face elevated AFib risk, and potentially for age-related AFib more broadly, this pathway could represent an actionable intervention target. Human trials would be needed to confirm therapeutic benefit.